Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
about
Optimal management of genital herpes: current perspectivesHerpes Genitalis: Diagnosis, Treatment and PreventionGenital Herpes: Insights into Sexually Transmitted Infectious DiseaseEnrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract.Identifying Risk Factors for Recent HIV Infection in Kenya Using a Recent Infection Testing Algorithm: Results from a Nationally Representative Population-Based SurveyMultipurpose Prevention Approaches with Antiretroviral-Based FormulationsCurrent Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract SheddingDifferential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical MucosaDetectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical TenofovirA randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymeraseAn update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy.The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II.Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis.Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.[The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. German version].Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
P2860
Q26746041-B9CA3F8F-F629-4A3E-AC05-03D7E127CA8CQ28067618-E723B786-E24D-4AE7-9649-D8CFF18228DDQ30235026-AE6AF2A7-EFF0-4FA8-ACFD-616B05EBFFA1Q33870372-63932802-DCDD-43F7-AFB5-62C91460C79BQ36022269-D07CE457-6C8A-409E-A40B-622905EB18E6Q36571872-02BE387A-127D-442D-A0C8-3B49BF941644Q36630996-57D417BB-30F0-4EE4-9AAA-20D3B60E07B9Q36644606-F76B24EE-9FCA-4458-8C8A-7DD181B280B0Q37203838-A20F5335-BA4E-4C18-905D-1C58FC5EBEA0Q37203904-7A1A303B-06BA-4F91-A8B7-01DFC8585744Q37277571-7D577B72-F762-4DE8-BDFC-23425B60AB3FQ37520083-86056B16-AF19-4DCF-896F-0CF5E6E2AA05Q37523020-CE3EF84E-1A68-44FC-94DC-A690F11994ACQ38689686-AA16574B-02B9-444E-B9C6-CC44E5A1D6A6Q39135864-2DCACF95-65F7-4453-806B-3A73DD006164Q40069410-25406AEB-3571-4B75-9C79-7646AC277E19Q40176907-BDE1D416-1E4E-4F18-BF61-0141DD8A0F74Q40201612-DE5A6DA4-42EB-4EED-80F3-D55846CC1BABQ40223007-966E0813-D394-46ED-987B-C608EF0CA697Q40333085-7BDEC525-23C1-4326-83E3-B70630919D0CQ47574658-B5CE32EC-FBF1-4CFA-8BF7-132BA967FEA9Q49926142-99118C3E-0D8A-4069-B20A-F3D135EB6823Q55514511-4BEC1F49-9C16-4A9F-ACE2-7576E1AE9365
P2860
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
@ast
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
@en
type
label
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
@ast
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
@en
prefLabel
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
@ast
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
@en
P2093
P2860
P50
P356
P1476
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection
@en
P2093
Angela Kashuba
Ayesha B M Kharsany
CAPRISA 004 Trial Group
Leila E Mansoor
P2860
P304
P356
10.1056/NEJMOA1410649
P407
P50
P577
2015-08-01T00:00:00Z